Astellas Reports 12-Week Results of Fezolinetant in the P-III (MOONLIGHT 1) Trial for the Nonhormonal Treatment of Vasomotor Symptoms in Asia
- The P-III (MOONLIGHT 1) trial evaluates fezolinetant (30mg, qd for 24wks.) in 302 women with mod. to sev. VMS related to menopause across China, Korea & Taiwan. The trial has been followed by a 12wk. non-controlled extension period
- The trial failed to meet its pre-defined EPs for efficacy @12wk. analysis, numerical improvements from baseline were observed. The results will be submitted for publication upon the completion of the 24wk. analyses
- Fezolinetant is a selective NK3 receptor antagonist & is designed to block NKB binding on the KNDy neuron to moderate neuronal activity in the thermoregulatory center of the brain to reduce the frequency & severity of VMS associated with menopause
Ref: PR Newswire | Image: Astellas
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.